Turn Biotechnologies
Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing a patented mRNA platform technology, ERA, the company is combating the effects of aging on the epigenome. The company’s proprietary mRNA platform technology, ERA and eTurna, a delivery platf...
Based based in Tokyo, Japan, Turn Biotechnologies works in health, founded in 2018.
Profile
"Turn Biotechnologies is a pioneering health company focused on developing innovative drugs to reverse aging and combat age-related diseases. Utilizing their patented mRNA platform technology, ERA, Turn Biotechnologies targets the effects of aging on the epigenome to restore optimal gene expression. Their proprietary mRNA platform technology, ERA, along with the eTurna delivery platform designed for nucleic acid therapeutics, enables the development of tailored therapies for immune-related diseases, cancer, dermatological conditions, ophthalmology, osteoarthritis, and the muscular system. By addressing the root causes of aging at the molecular level, Turn Biotechnologies is at the forefront of revolutionizing healthcare and potentially extending human lifespan."
Its activity falls under health; the profile below is assembled from public directory data.
The company is recorded as being based in Tokyo, Japan.
Directory data places it at the Plug and Play portfolio startup stage.
Recorded headcount: 11-50 employees.
| Sector | Health |
|---|---|
| Headquarters | Tokyo, Japan |
| Country | United States |
| Founded | 2018 |
| Employees | 11-50 |
| Stage | Plug and Play portfolio startup |
Website: turn.bio
Create a free account